• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

解析诱导多能干细胞衍生神经元中Ataxin-2和TDP-43的相互作用组以寻找潜在的肌萎缩侧索硬化症靶点。

Deciphering the interactome of Ataxin-2 and TDP-43 in iPSC-derived neurons for potential ALS targets.

作者信息

Tian Yuan, Heinsinger Nicolette, Hu Yinghui, Lim U-Ming, Wang Yi, Fernandis Aaron Zefrin, Parmentier-Batteur Sophie, Klein Becky, Uslaner Jason M, Smith Sean M

机构信息

Neuroscience, Merck Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, United States of America.

Quantatitive Biosciences, Merck Sharp & Dohme, Singapore, Singapore.

出版信息

PLoS One. 2024 Dec 31;19(12):e0308428. doi: 10.1371/journal.pone.0308428. eCollection 2024.

DOI:10.1371/journal.pone.0308428
PMID:39739690
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11687654/
Abstract

Ataxin-2 is a protein containing a polyQ extension and intermediate length of polyQ extensions increases the risk of Amyotrophic Lateral Sclerosis (ALS). Down-regulation of Ataxin-2 has been shown to mitigate TDP-43 proteinopathy in ALS models. To identify alternative therapeutic targets that can mitigate TDP-43 toxicity, we examined the interaction between Ataxin-2 and TDP-43. Co-immunoprecipitation demonstrated that Ataxin-2 and TDP-43 interact, that their interaction is mediated through the RNA recognition motif (RRM) of TDP-43, and knocking down Ataxin-2 or mutating the RRM domains rescued TDP-43 toxicity in an iPSC-derived neuronal model with TDP-43 overexpression. To decipher the Ataxin-2 and TDP-43 interactome, we used co-immunoprecipitation followed by mass spectrometry to identify proteins that interacted with Ataxin-2 and TDP-43 under conditions of endogenous or overexpressed TDP-43 in iPSC-derived neurons. Multiple interactome proteins were differentially regulated by TDP-43 overexpression and toxicity, including those involved in RNA regulation, cell survival, cytoskeleton reorganization, protein modification, and diseases. Interestingly, the RNA-binding protein (RBP), TAF15 which has been implicated in ALS was identified as a strong binder of Ataxin-2 in the condition of TDP-43 overexpression. Together, this study provides a comprehensive annotation of the Ataxin-2 and TDP-43 interactome and identifies potential therapeutic pathways and targets that could be modulated to alleviate Ataxin-2 and TDP-43 interaction-induced toxicity in ALS.

摘要

ataxin-2是一种含有多聚谷氨酰胺(polyQ)扩展的蛋白质,中等长度的polyQ扩展会增加肌萎缩侧索硬化症(ALS)的风险。在ALS模型中,ataxin-2的下调已被证明可减轻TDP-43蛋白病。为了确定可以减轻TDP-43毒性的替代治疗靶点,我们研究了ataxin-2与TDP-43之间的相互作用。免疫共沉淀表明ataxin-2与TDP-43相互作用,它们的相互作用是通过TDP-43的RNA识别基序(RRM)介导的,并且敲低ataxin-2或突变RRM结构域可在TDP-43过表达的诱导多能干细胞(iPSC)衍生的神经元模型中挽救TDP-43毒性。为了解析ataxin-2和TDP-43相互作用组,我们使用免疫共沉淀然后进行质谱分析,以鉴定在iPSC衍生的神经元中内源性或过表达TDP-43的条件下与ataxin-2和TDP-43相互作用的蛋白质。多种相互作用组蛋白受TDP-43过表达和毒性的差异调节,包括那些参与RNA调节、细胞存活、细胞骨架重组、蛋白质修饰和疾病的蛋白。有趣的是,在TDP-43过表达的情况下,与ALS有关的RNA结合蛋白(RBP)TAF15被鉴定为ataxin-2的强结合蛋白。总之,本研究提供了ataxin-2和TDP-43相互作用组的全面注释,并确定了潜在的治疗途径和靶点,这些途径和靶点可以被调节以减轻ataxin-2和TDP-43相互作用诱导的ALS毒性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c84/11687654/f6029ba692f5/pone.0308428.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c84/11687654/a0854975af7e/pone.0308428.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c84/11687654/6784d7e99cfc/pone.0308428.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c84/11687654/61e3bb24904a/pone.0308428.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c84/11687654/dd556c4626ef/pone.0308428.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c84/11687654/ad9bda982f17/pone.0308428.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c84/11687654/f6029ba692f5/pone.0308428.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c84/11687654/a0854975af7e/pone.0308428.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c84/11687654/6784d7e99cfc/pone.0308428.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c84/11687654/61e3bb24904a/pone.0308428.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c84/11687654/dd556c4626ef/pone.0308428.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c84/11687654/ad9bda982f17/pone.0308428.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c84/11687654/f6029ba692f5/pone.0308428.g006.jpg

相似文献

1
Deciphering the interactome of Ataxin-2 and TDP-43 in iPSC-derived neurons for potential ALS targets.解析诱导多能干细胞衍生神经元中Ataxin-2和TDP-43的相互作用组以寻找潜在的肌萎缩侧索硬化症靶点。
PLoS One. 2024 Dec 31;19(12):e0308428. doi: 10.1371/journal.pone.0308428. eCollection 2024.
2
Ataxin-2 polyglutamine expansions aberrantly sequester TDP-43 ribonucleoprotein condensates disrupting mRNA transport and local translation in neurons.ataxin-2多聚谷氨酰胺扩增异常隔离TDP-43核糖核蛋白凝聚物,破坏神经元中的mRNA转运和局部翻译。
Dev Cell. 2025 Jan 20;60(2):253-269.e5. doi: 10.1016/j.devcel.2024.09.023. Epub 2024 Oct 16.
3
Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice.ataxin-2的治疗性减少可延长TDP-43小鼠的寿命并减轻病理变化。
Nature. 2017 Apr 20;544(7650):367-371. doi: 10.1038/nature22038. Epub 2017 Apr 12.
4
ALS-associated ataxin 2 polyQ expansions enhance stress-induced caspase 3 activation and increase TDP-43 pathological modifications.ALS 相关共济失调 2 聚谷氨酰胺扩展增强应激诱导的半胱天冬酶 3 激活,并增加 TDP-43 病理修饰。
J Neurosci. 2012 Jul 4;32(27):9133-42. doi: 10.1523/JNEUROSCI.0996-12.2012.
5
Distinct TDP-43 pathology in ALS patients with ataxin 2 intermediate-length polyQ expansions.ALS 患者伴有的 ataxin 2 中间长度 polyQ 扩展存在独特的 TDP-43 病理学。
Acta Neuropathol. 2012 Aug;124(2):221-30. doi: 10.1007/s00401-012-0985-5. Epub 2012 Apr 21.
6
ATAXIN-2 intermediate-length polyglutamine expansions elicit ALS-associated metabolic and immune phenotypes.ATAXIN-2 中间长度多聚谷氨酰胺扩展引起 ALS 相关代谢和免疫表型。
Nat Commun. 2024 Aug 29;15(1):7484. doi: 10.1038/s41467-024-51676-0.
7
Distinct responses of neurons and astrocytes to TDP-43 proteinopathy in amyotrophic lateral sclerosis.在肌萎缩侧索硬化症中,神经元和星形胶质细胞对 TDP-43 蛋白病的反应不同。
Brain. 2020 Feb 1;143(2):430-440. doi: 10.1093/brain/awz419.
8
Comparative interactomics analysis of different ALS-associated proteins identifies converging molecular pathways.不同肌萎缩侧索硬化症相关蛋白的比较相互作用组学分析确定了趋同的分子途径。
Acta Neuropathol. 2016 Aug;132(2):175-196. doi: 10.1007/s00401-016-1575-8. Epub 2016 May 10.
9
Modeling of TDP-43 proteinopathy by chronic oxidative stress identifies rapamycin as beneficial in ALS patient-derived 2D and 3D iPSC models.通过慢性氧化应激对TDP-43蛋白病进行建模,确定雷帕霉素对ALS患者来源的二维和三维诱导多能干细胞模型有益。
Exp Neurol. 2025 Jan;383:115057. doi: 10.1016/j.expneurol.2024.115057. Epub 2024 Nov 12.
10
Intracellular dynamics of Ataxin-2 in the human brains with normal and frontotemporal lobar degeneration with TDP-43 inclusions.在具有 TDP-43 包涵体的正常和额颞叶变性的人脑内 Ataxin-2 的细胞内动力学。
Acta Neuropathol Commun. 2020 Oct 28;8(1):176. doi: 10.1186/s40478-020-01055-9.

本文引用的文献

1
Intermediate Repeat Expansion in the Gene as a Risk Factor in the ALS and FTD Spanish Population.基因中的中间重复序列扩增作为西班牙人群肌萎缩侧索硬化症和额颞叶痴呆的一个风险因素。
Biomedicines. 2024 Feb 2;12(2):356. doi: 10.3390/biomedicines12020356.
2
AAV-based delivery of RNAi targeting Ataxin-2 improves survival, strength, and pathology in mouse models of rapidly and slowly progressive sporadic ALS.基于腺相关病毒载体递送靶向ataxin-2的RNA干扰可改善快速和缓慢进展性散发性肌萎缩侧索硬化症小鼠模型的存活率、肌肉力量及病理状况。
bioRxiv. 2024 Feb 2:2024.01.31.578314. doi: 10.1101/2024.01.31.578314.
3
ASO drug Qalsody (tofersen) targets amyotrophic lateral sclerosis.
反义寡核苷酸药物Qalsody(托非生)靶向肌萎缩侧索硬化症。
Trends Pharmacol Sci. 2023 Dec;44(12):1043-1044. doi: 10.1016/j.tips.2023.08.008. Epub 2023 Sep 12.
4
Neuroinflammatory Pathways in the ALS-FTD Continuum: A Focus on Genetic Variants.ALS-FTD 连续体中的神经炎症途径:关注遗传变异。
Genes (Basel). 2023 Aug 21;14(8):1658. doi: 10.3390/genes14081658.
5
The era of cryptic exons: implications for ALS-FTD.隐匿外显子的时代:对 ALS-FTD 的影响。
Mol Neurodegener. 2023 Mar 15;18(1):16. doi: 10.1186/s13024-023-00608-5.
6
Drug discovery and amyotrophic lateral sclerosis: Emerging challenges and therapeutic opportunities.药物研发与肌萎缩侧索硬化症:新出现的挑战与治疗机遇
Ageing Res Rev. 2023 Jan;83:101790. doi: 10.1016/j.arr.2022.101790. Epub 2022 Nov 17.
7
Genome-wide CRISPR screen reveals v-ATPase as a drug target to lower levels of ALS protein ataxin-2.全基因组 CRISPR 筛选揭示 v-ATPase 是降低 ALS 蛋白 ataxin-2 水平的药物靶点。
Cell Rep. 2022 Oct 25;41(4):111508. doi: 10.1016/j.celrep.2022.111508.
8
Synaptic dysfunction in ALS and FTD: anatomical and molecular changes provide insights into mechanisms of disease.肌萎缩侧索硬化症和额颞叶痴呆中的突触功能障碍:解剖学和分子变化为疾病机制提供了见解。
Front Mol Neurosci. 2022 Oct 3;15:1000183. doi: 10.3389/fnmol.2022.1000183. eCollection 2022.
9
Multiple roles for the cytoskeleton in ALS.细胞骨架在肌萎缩侧索硬化症中的多种作用。
Exp Neurol. 2022 Sep;355:114143. doi: 10.1016/j.expneurol.2022.114143. Epub 2022 Jun 14.
10
Antisense Oligonucleotides for the Study and Treatment of ALS.反义寡核苷酸在肌萎缩侧索硬化症研究和治疗中的应用。
Neurotherapeutics. 2022 Jul;19(4):1145-1158. doi: 10.1007/s13311-022-01247-2. Epub 2022 Jun 2.